Nervous System Diseases

1,005 trials 421 recruiting

Filter these 1,005 trials by phase, country and sponsor.

Open in Search →

A phase II trial of 177Lutetium-DOTATATE in children with primary refractory or relapsed high-risk neuroblastoma LuDO-N Ended

2023-503684-42-00 Neuroblastoma 4 2026-02-20
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer’s Disease (TRAILBLAZER-ALZ 5) Ended

2025-522340-40-00 Alzheimer Disease Dementia Brain Diseases Central 5 2025-12-04
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Partici… Ended

2025-521127-73-00 Relapsing forms of Multiple Sclerosis 5 2025-09-12
A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety between ABP 692… Ended

2024-512914-16-00 Relapsing-remitting Multiple Sclerosis 5 2025-09-12
A study to assess the efficacy and safety of Empasiprubart versus IVIg in adults with Multifocal Motor Neuropathy Ended

2024-516473-72-00 Multifocal Motor Neuropathy 5 2025-07-31
A Study of ABBV-CLS-628 in Adult Subjects with Autosomal Dominant Polycystic Kidney Disease Ended

2024-517143-31-00 Autosomal Dominant Polycystic Kidney Disease 4 2025-07-18
Comparative PK, PD, efficacy, safety and immunogenicity assessment of the proposed ocrelizumab biosimilar CYB704 and Ocrevus in participants… Ended

2024-512319-40-00 Subjects with relapsing multiple sclerosis (relapsing r 5 2025-07-01
Phase 2 Study of CVN424 Ended

2024-516811-25-00 Parkinson Disease 4 2025-05-15
A Double-Blind, Randomized, Placebo-Controlled, Phase 1b Study to Assess the Safety, Tolerability, and Pharmacokinetics of Multiple Ascendin… Ended

2024-519899-72-00 Alzheimer's Disease 3 2025-05-08
AN INTERVENTIONAL, EFFICACY, AND SAFETY, PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY WITH AN OPEN-LABEL EXTENSION TO INVESTI… Ended

2023-505601-16-00 Chronic Migraine 5 2025-04-22
A Study of Remternetug in Early Alzheimer’s Disease Ended

2024-515656-20-00 Alzheimer’s Disease 5 2025-04-15
A trial of Lu AF82422 in Participants with Multiple System Atrophy (MSA) Ended

2024-517169-18-00 Multiple System Atrophy 5 2025-04-10
A trial to find the effect of Ginkgo biloba extract EGb 761® and how safe it is in participants with cognitive impairment associated with po… Ended

2024-517199-39-00 COGNITIVE IMPAIRMENT ASSOCIATED WITH POST-COVID-19 SYND 4 2025-03-19
A Study to Evaluate the Efficacy, Safety, and Tolerability of Atogepant for the Preventive Treatment of Menstrual Migraine Ended

2024-512946-41-00 Menstrual Migraine 5 2025-03-05
Safety and exploratory efficacy of AMT-162 for adults with SOD1 ALS Ended

2024-517244-57-00 Amyotrophic Lateral Sclerosis (ALS) 9 2025-03-03
Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson’s Disease (LRRK2-PD) Ended

2024-513384-15-00 Parkinson’s disease 4 2025-02-13
Cladribine for the treatment of secondary progressive MS - randomized, double-blind, placebo-controlled study. Ended

2024-516992-33-02 Multiple sclerosis secondary progressive form 4 2025-01-30
SYNERGY OSA Ended

2023-510519-20-00 Obstructive sleep apnea with an incomplete clinical res 4 2024-12-12
Efficacy and safety study of frexalimab (SAR441344) in adults with nonrelapsing secondary progressive multiple sclerosis Ended

2023-504359-29-01 Multiple sclerosis 5 2024-12-11
Impact of microglial activation on synaptic density in Alzheimer’s disease Ended

2024-516566-11-00 Alzeihmer disease 4 2024-11-29
A study to learn about the safety of long-term treatment with brivaracetam in children and young adults with childhood or juvenile absence e… Ended

2023-508095-11-00 Childhood Absence Epilepsy 5 2024-11-27
Efficacy and safety study of frexalimab (SAR441344) in adults with relapsing forms of multiple sclerosis Ended

2024-514343-29-00 multiple sclerosis 5 2024-11-19
RCT of Medical Cannabis Aerosol for DPNP Treatment Ended

2023-508932-68-00 Diabetic Peripheral Neuropathic Pain 4 2024-11-14
Therapeutic evaluation of low-dose IL-2-based immunomodulatory approach in patients with early Alzeihmer Disease Ended

2024-516565-36-00 Alzheimer Disease 4 2024-11-14